Objective: The purpose of this study is to investigate the single dose pharmaco-kinetics of lithium in Taiwanese/Chinese bipolar patients for future interracial comparisons.
Method: Eight bipolar patients took 900 mg of lithium carbonate after overnight fasting. Blood samples of 5 mL were taken after 15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 7 h, 9 h, 15 h, 25 h and 31 h after dosing. The computer programs CSTRIP and PCNONLIN were used for pharmacokinetic analysis.
Results: The pharmacokinetic parameters obtained were as follows: Cmax, 0.970 ± 0.170 (SD) mmoi/L; Tmax, 1.59 ± 0.78 h; AUC31h = 548.9 ± 135.4 mmol.m/L; AUC = 722.6 ± 262.7 mmol.m/L; β-half-life = 16.3 ± 7.18 h; K-half-life = 0.613 ± 0.442 h; CIoral = 1.13 ± 0.39 mL/min/kg; Vd/F = 1.43 ± 0.387 L/kg. Most of the pharmacokinetic parameters were within the ranges reported in investigations of Caucasian subjects.
Conclusions: This study showed that racial differences in lithium pharmacokinetics might not exist. We suggest that methodological designs, including method of blood sampling, measurement of lithium, and pharmacokinetic and statistical calculations, be standardised if future cross-ethnic comparisons are to be conducted.
LinKMPolandREPharmacotherapy of Asian patients. Psychiatry Annuals1980; 19:659–663.
6.
LinKMFinderE.Neuroleptic dosage in Asians. American Journal of Psychiatry1983; 140:490–491.
7.
PotkinSGShenYPardesHHaloperidol concentrations elevated in Chinese patients. Psychiatry Research1984; 12:167–172.
8.
ChangWHChenTYLeeCFHuWHYehEKLow plasma reduced haloperidol/haloperidol ratios in Chinese patients. Biological Psychiatry1987; 22:1406–1408.
9.
LinKMPolandRELesserIMEthnicity and psychopharmacology. Culture, Medicine and Psychiatry1986; 10:151–165.
10.
WoodAJZhouHHEthnic differences in drug disposition and responsiveness. Clinical Pharmacokinetics1991; 20:1–24.
11.
MendozaRSmithMWPolandRELinKMStricklandTLEthnic psychopharmacology: the Hispanic and native American perspective. Psychopharmacology Bulletin1991; 27:449–461.
12.
StricklandTLRanganathVLinKMPolandREMendozaRSmithMWPsychopharmacologic considerations in the treatment of black American populations. Psychopharmacology Bulletin1991; 27:441–448.
13.
LinKMPolandRESmithMWStricklandTLMendozaR.Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacology Bulletin1991; 27:427–439.
14.
SedmanAJWagnerJGCstrip, a FORTRAN IV computer program for obtaining initial polyexponential parameter estimates. Journal of Pharmacological Science1976; 65:1006–1010.
TakahashiRNakaneYAkiyamaA.Lithium treatment in affective disorders from viewpoint of transcultural psychopharmacology: therapeutic plasma level. Folia psychiatrica et Neurologica Japonica1979; 33:501–509.
18.
ChangSSPandeyGNZhangMYKuNFDavisJM‘Racial differences in plasma and RBC lithium levels'. Paper presented at the annual meeting of American Psychiatric Association. Continuing Medical Education Syllabus and Scientific Proceedings1984; 11:239–240.
19.
ChangSSPandeyGNYangYYYehEKDavisJM‘Lithium pharmacokinetics: Interracial comparison’. Paper presented at the 138th Annual Meeting of the American Psychiatric Association. Dallas, Texas, May 1985.
20.
YangYYProphylactic efficacy of lithium and its effective plasma levels in Chinese bipolar patients. Acta Psychiatrica Scandinavica1985; 71:171–175.
21.
YangYYYehEKChangSSDengHCLeeCFMaintenance lithium levels could be lowered: based on Taiwanese and Danish studies. Journal of the Formosan Medical Association1991; 90:509–513.
22.
TsengHYChenCCWenJKThe single dose bioavailability of different lithium carbonate products. Journal of the Formosan Medical Association1987; 86:543–548.
23.
CaldwellHCWestlakeWJConnorSMJamesNHA pharmacokinetic analysis of lithium carbonate absorption from several formulations in man. Journal of Clinical Pharmacology1971; 11:349–356.
24.
AltamuraACGomeniRSacchettiESmeraldiE.Plasma and intracellular kinetics of lithium after oral administration of various lithium salts. European Journal of Clinical Pharmacology1977; 12:59–63.
25.
AmdisenA.Serum level monitoring and clinical pharmacolinetics of lithium. Clinical Pharmacokinetics1977; 2:73–92.
26.
MasonRWMcQueenEGKeargPJJamesNMPharmacokinetics of lithium: elimination half-time, renal clearance and apparent volume of distribution of schizophrenia. Clinical Pharmacokinetics1978; 3:241–246.
27.
Nielsen-KudskAmdisen A.Analysis of the pharmacokinetics of lithium in man. European Journal of Clinical Pharmacology1979; 16:271–277.